Bausch Health Companies (BHC) Set to Announce Earnings on Wednesday

Bausch Health Companies (NYSE:BHC - Get Free Report) is scheduled to announce its earnings results after the market closes on Wednesday, October 30th. Analysts expect the company to announce earnings of $1.05 per share for the quarter. Bausch Health Companies has set its FY 2024 guidance at EPS.Investors interested in registering for the company's conference call can do so using this link.

Bausch Health Companies (NYSE:BHC - Get Free Report) last announced its quarterly earnings data on Thursday, August 1st. The company reported $0.98 EPS for the quarter, topping analysts' consensus estimates of $0.89 by $0.09. Bausch Health Companies had a negative return on equity of 742.06% and a negative net margin of 5.12%. The company had revenue of $2.40 billion during the quarter, compared to the consensus estimate of $2.33 billion. During the same quarter last year, the company earned $0.81 EPS. On average, analysts expect Bausch Health Companies to post $4 EPS for the current fiscal year and $4 EPS for the next fiscal year.

Bausch Health Companies Stock Down 0.5 %

Shares of BHC stock traded down $0.04 during mid-day trading on Wednesday, reaching $8.07. The stock had a trading volume of 854,184 shares, compared to its average volume of 2,962,118. The firm's 50 day simple moving average is $7.17 and its 200 day simple moving average is $7.08. Bausch Health Companies has a one year low of $3.96 and a one year high of $11.46. The firm has a market cap of $2.91 billion, a PE ratio of -6.51 and a beta of 0.77.

Analysts Set New Price Targets

Several equities analysts recently commented on BHC shares. Jefferies Financial Group cut their target price on Bausch Health Companies from $13.00 to $9.00 and set a "buy" rating for the company in a research report on Wednesday, August 7th. Truist Financial cut their target price on Bausch Health Companies from $8.00 to $7.00 and set a "hold" rating for the company in a research report on Thursday, July 25th. Piper Sandler downgraded Bausch Health Companies from a "neutral" rating to an "underweight" rating and cut their target price for the stock from $9.00 to $3.00 in a research report on Friday, August 2nd. StockNews.com downgraded Bausch Health Companies from a "buy" rating to a "hold" rating in a research report on Thursday, October 17th. Finally, Royal Bank of Canada cut their target price on Bausch Health Companies from $10.00 to $8.50 and set a "sector perform" rating for the company in a research report on Friday, August 2nd. One analyst has rated the stock with a sell rating, six have given a hold rating and one has assigned a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of "Hold" and an average target price of $7.33.

Insider Activity at Bausch Health Companies

In related news, EVP Seana Carson sold 13,370 shares of the firm's stock in a transaction on Friday, September 6th. The stock was sold at an average price of $6.21, for a total transaction of $83,027.70. Following the completion of the sale, the executive vice president now directly owns 435,198 shares of the company's stock, valued at $2,702,579.58. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 8.12% of the company's stock.

Bausch Health Companies Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.